| Number | Title | Target
accrual |
| EORTC Breast Cancer Group |
75111
10114 | Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH/PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group Study Coordinator: Hans P.M.W. Wildiers, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 80 |
| EORTC Cancer in Elderly Task Force |
75111
10114 | Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH/PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group Study Coordinator: Hans P.M.W. Wildiers, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 80 |
| EORTC Endocrine Task Force |
1209
| A phase II study exploring the safety and efficacy of BIBF1120 as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. Study Coordinator: Martin Schlumberger, Institut Gustave Roussy, Villejuif
| 150 |
| EORTC Gastrointestinal Tract Cancer Group |
22114
40111 | Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomized phase II/III trial of preoperative chemotherapy for resectable gastric cancer (TOP GEAR) Study Coordinator: Karin Haustermans, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 120 |
40CRC
SPECTAcolor | An EORTC prospective screening initiative for the determination of molecular parameters for advanced colorectal cancer Study Coordinator: Gunnar Folprecht, Universitaetsklinikum Carl Gustav Carus, Dresden
| |
| EORTC Genito-Urinary Cancers Group |
1211
| Phase II randomized comparative trial of TAK-700 (orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration. Study Coordinator: Cora Sternberg, San Camillo Forlanini Hospitals, Roma
| 200 |
| EORTC Gynecological Cancer Group |
55116
62114 | A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma Study Coordinator: Rene Verheijen, Universitair Medisch Centrum - Academisch Ziekenhuis, Utrecht
| 216 |
| EORTC Imaging Group |
1211
| Phase II randomized comparative trial of TAK-700 (orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration. Study Coordinator: Cora Sternberg, San Camillo Forlanini Hospitals, Roma
| 200 |
| EORTC Radiation Oncology Group |
22114
40111 | Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomized phase II/III trial of preoperative chemotherapy for resectable gastric cancer (TOP GEAR) Study Coordinator: Karin Haustermans, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 120 |
| EORTC Soft Tissue and Bone Sarcoma Group |
55116
62114 | A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma Study Coordinator: Rene Verheijen, Universitair Medisch Centrum - Academisch Ziekenhuis, Utrecht
| 216 |